Navigation Links
ThromboGenics Completes Patient Enrolment in US Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease
Date:9/23/2009

er on the milestones needed to build a strong, successful and profitable Company."

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications. In addition, ThromboGenics is developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting anti-coagulant, and TB-403 (anti-PlGF) for cancer.

ThromboGenics has built strong links with the University of Leuven and the Flanders Institute for Biotechnology (VIB) and has exclusive rights to certain therapeutics developed at these institutions. ThromboGenics is headquartered in Leuven, Belgium. The Company is listed on Eurolist by Euronext Brussels under the symbol THR. More information is available at http://www.thrombogenics.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. ThromboGenics Microplasmin Phase III Program Progressing According to Schedule
7. ThromboGenics and BioInvent Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study With TB-402
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
11. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ) today ... Bank Health Care Conference to be held May 29-30 ... Adrian Adams , Chief Executive Officer and President, ... and its product pipeline at 12:00 p.m. ET on ... http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The presentation will also be ...
(Date:5/24/2013)... , May 24, 2013  Sinovac Biotech ... provider of biopharmaceutical products in China ... operating subsidiary company of Sinovac, obtained the Certificate ... Certificate) from the China State and Food Administration ... bulk production plants, and its Changping filing and ...
(Date:5/24/2013)... England and BOSTON , May ... drug discovery and development company, is pleased to announce that it ... Consultant to augment the Company,s business development capabilities in ... has more than 15 years of experience in business development, licensing ... Perlegen Sciences, Inc., Roche Pharma ( Japan ), Nippon ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 4Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 2Sinovac Beijing Obtains China GMP Certificate Under the New GMP Guidelines 3Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2
... Medical Technologies, Inc., announced today the availability of ... ™ as a native application for Apple,s iPad® ... integrates functionality accessed on handheld devices directly with ... and interoperability solution PrimeSUITE ® 2011. ...
... Sciences International, Inc. (Nasdaq: BDSI ) today ... Mark A. Sirgo, President and Chief Executive Officer, will ... BDSI,s product pipeline, particularly BEMA Buprenorphine for the treatment ... Phase 3 efficacy study is anticipated in late September, ...
Cached Medicine Technology:Greenway's Remote Clinic PrimeMOBILE Available on Apple's iPad 2Greenway's Remote Clinic PrimeMOBILE Available on Apple's iPad 3BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences 2BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences 3
(Date:5/25/2013)... (PRWEB) May 25, 2013 Actos ... underway in U.S. District Court, Western District of Louisiana, ... According to a Case Management Order issued on May ... filing of contested motions in the Actos bladder cancer ... (In re: Actos Product Liability Litigation, MDL No. 2299) ...
(Date:5/25/2013)... States (PRWEB) May 25, 2013 ... largest underground shelter company in the US and ... underground structures for over 35 years. M.E. and ... U.S. Handbook of NBC Weapon Fundamentals and Shelter ... United States’ bible on shelter engineering. McCarthy is ...
(Date:5/25/2013)... On May 20, 2013 the Sydney Morning ... discuss or plan for their eventual demise, but it is ... a Must-Do List to help people properly arrange for their ... personal fact sheet.” , While not a formal document, this ... data. It may include a summary of assets, debts, ...
(Date:5/25/2013)... NY (PRWEB) May 25, 2013 On ... to brain cancer research and advocacy, comments on a ... Physics, that shows incorporating cold atmospheric plasma into brain ... , According to a Science Daily ... Physics (MPE), biologists and physicians demonstrated the “synergistic effect ...
(Date:5/25/2013)... May 25, 2013 According to world-renowned ... beautiful and powerful women that ever lived. Cleopatra’s legendary ... some of the most powerful men in her time. ... remedies to keep her skin glowing and fresh, from ... bees- wax, maringa oil and cyprus grass. , Cleopatra ...
Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:FuneralFinancials.com Releases Last Wishes Must-Do List 2Health News:Voices Against Brain Cancer Comments on Study that Shows Cold Plasma’s Success Against Brain Cancer Cells 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 2Health News:The Cleopatra Lift - A New Non Surgical Option to Aging Offered by Vancouver Physician 3
... as firm-wide resourceHOUSTON, March 2 Confirming their commitment ... WHR Architects announced that Laurie Waggener, RRT, IIDA, AAHID ... Resource Studio. A recognized leader in the field ... of research as a means of enhancing the value ...
... $1 Billion per YearJACKSONVILLE, Fla., March 2 ... announced its support of the Medical Group Management ... is intended to advance the adoption of standardized ... by January 1, 2010. MGMA estimates that machine-readable ...
... Corp. (Nasdaq: KOOL ), a leading developer and ... announced today that products derived from its Intellectual Property have ... cord blood in more than one million procedures since the ... cells have been used to reconstitute the blood cell forming ...
... BMRN ) announced today the appointment of Dr. ... (CMO). Dr. Fuchs will replace,longtime BioMarin CMO, Dr. Emil Kakkis. ... welcome Dr. Henry Fuchs to BioMarin. He is,uniquely qualified to ... and CEO, he has demonstrated a strength of vision and,execution ...
... Launch to Include 24-oz and Convenient 4-oz Travel ... Bioscience (Nasdaq: PURE ) today announced ... of PURE,s silver dihydrogen citrate (SDC)-based disinfectant as ... Laboratories, OneShot Plus product line. OneShot Plus ...
... Profitability in Fourth Quarter of Fiscal 2008OLDSMAR, Fla., ... Board: CCEL) (the "Company"), one of the world,s ... and an industry leader of innovative stem cell ... for the fiscal year ended November 30, 2008 ...
Cached Medicine News:Health News:Laurie Waggener Joins WHR Architects 2Health News:Availity Announces Support of Project SwipeIT 2Health News:Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone 2Health News:Thermogenesis Technology Products Surpass Processing of More Than One Million Units of Cord Blood Stem Cells at 10-Year Milestone 3Health News:BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer 2Health News:BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer 3Health News:BioMarin Appoints Dr. Henry J. Fuchs as Senior Vice President and Chief Medical Officer 4Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 2Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 3Health News:Sterifide Laboratories to Launch 'Powered by SDC' OneShot Plus Disinfectant and Deodorizer 4Health News:Cryo-Cell International, Inc. Reports Results for Fiscal 2008 2Health News:Cryo-Cell International, Inc. Reports Results for Fiscal 2008 3Health News:Cryo-Cell International, Inc. Reports Results for Fiscal 2008 4Health News:Cryo-Cell International, Inc. Reports Results for Fiscal 2008 5Health News:Cryo-Cell International, Inc. Reports Results for Fiscal 2008 6
... are ideal for PCR and ... any work where aerosol contamination ... for pipetting DNA/RNA solutions, infectious ... For applications requiring absolute sterility, ...
... ART Aerosol Resistant Tips offer a ... ART Tips are designed for applications such ... studies. In addition, ART Tips are excellent ... and forensic studies. ART Tips prevent aerosol ...
Diamond Filter Tips play a critical role in preventing aerosol-borne contamination. Also available sterilized (no need to autoclave) and certified free of detectable RNase, DNase, DNA, RNA, and prote...
1000 L, Racked, Pre-sterilized, 100 tips/rack Recommended for 500 and 1000 L pipettes....
Medicine Products: